Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5193666
Max Phase: Preclinical
Molecular Formula: C23H25ClN2O3S
Molecular Weight: 444.98
Associated Items:
ID: ALA5193666
Max Phase: Preclinical
Molecular Formula: C23H25ClN2O3S
Molecular Weight: 444.98
Associated Items:
Canonical SMILES: Cc1cc(CC(=O)O)cc(OCCC2CCN(c3nc4ccc(Cl)cc4s3)CC2)c1
Standard InChI: InChI=1S/C23H25ClN2O3S/c1-15-10-17(13-22(27)28)12-19(11-15)29-9-6-16-4-7-26(8-5-16)23-25-20-3-2-18(24)14-21(20)30-23/h2-3,10-12,14,16H,4-9,13H2,1H3,(H,27,28)
Standard InChI Key: ZPVDMEPVFBETQM-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 444.98 | Molecular Weight (Monoisotopic): 444.1274 | AlogP: 5.57 | #Rotatable Bonds: 7 |
Polar Surface Area: 62.66 | Molecular Species: ACID | HBA: 5 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 4.16 | CX Basic pKa: 2.47 | CX LogP: 6.00 | CX LogD: 3.08 |
Aromatic Rings: 3 | Heavy Atoms: 30 | QED Weighted: 0.52 | Np Likeness Score: -1.57 |
1. Kato T, Ohara T, Suzuki N, Muto S, Tokuyama R, Mizutani M, Fukasawa H, Matsumura KI, Itai A.. (2022) Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method., 59 [PMID:35063634] [10.1016/j.bmcl.2022.128567] |
Source(1):